77.8% Efficacy showed in Covaxin Phase-III Trial
The hard work of the scientists and the researchers finally gets better acclamation
Published:
05 Jul 2021 02:00pm IST
05 Jul 2021 02:00pm IST
The Hyderabad based Bharat Biotech India Ltd (BBIL) has announced the safety and efficacy analysis data from phase-3 trials of Covaxin, which is developed in partnership with NIV-ICMR (National Institute of Virology-Indian Council of Medical Research Director). The company on July 3 publicised the long-awaited results of the Phase-3 trial of Covaxin that involved nearly 25,800 volunteers spanning 25 hospitals across the country.
Covaxin is found to be 77.8% effective against symptomatic Covid-19 in the efficacy analysis demonstrated through evaluation of 130 confirmed cases. The company said that it was 93.4 per cent 'effective' against severe symptomatic Covid and gave 63.6 per cent protection against asymptomatic Covid.
Speaking on the results, the Director of the National Institute of Virology, Dr Priya Abraham said that it was great to have the phase III clinical trials of Covaxin after its efficacy was found to be 77.8 %.
Abraham informed that the ICMR-NIV and BBIL(Bharat Biotech) had a wonderful interaction during the exhilarating journey. Sera from Covaxin recipients have also been evaluated against the viral variants detected in India like Alpha, Beta, Zeta, Kappa and Delta. Abraham added that the production of this vaccine in India is a matter of pride for every Indian.
Covaxin has now received emergency use authorizations in 16 countries including Brazil, India, the Philippines, Iran, Mexico, etc. The company is discussing with WHO to obtain an emergency use listing for Covaxin.
Covaxin has now received emergency use authorizations in 16 countries including Brazil, India, the Philippines, Iran, Mexico, etc. The company is discussing with WHO to obtain an emergency use listing for Covaxin.
The Director-General of IMCR and the Secretary of the Department of Health expressed their goodwill towards the Bharat Biotech for the production of Covaxin and said this particular vaccine has been successful in showing the efficacy of 77.8% in India's largest phase III trial so far. In the end, it was added that the scientists at the ICMR and BBIL have worked tirelessly to make Covaxin effective in fighting any variant of the virus.
Bharat Biotech is now continuing with additional clinical trials of Covaxin to establish safety and efficacy in children between 2-18 years of age. A clinical trial to determine the safety and immunogenicity of a booster dose is also in process.
Be the first to start a discussion here. Sign-in to write a comment now!
